by Madaline Spencer | Nov 20, 2025
The U.S. Food and Drug Administration (FDA) has approved Komzifti (ziftomenib) for the treatment of relapsed or refractory (R/R) acute myeloid leukemia (AML) with susceptible NPM1 mutation. Acute myeloid leukemia (AML) is a cancer that affects the blood and bone...
by Madaline Spencer | Nov 18, 2025
Aman Chauhan, MD, Oncologist at the University of Miami, discusses details of a phase 3 study testing paltusotine in patients with carcinoid syndrome due to neuroendocrine tumors (NETs). NETs are rare tumors that usually develop in the GI tract or lungs,...
by Madaline Spencer | Nov 17, 2025
Alexandra C. Bayer Wildberger, PhD, Post-Doctoral Associate at Yale School of Medicine, discusses the shift to precision medicine in myasthenia gravis (MG). MG is a chronic autoimmune neuromuscular disease characterized by weakness of the skeletal...
by Madaline Spencer | Nov 14, 2025
Naomi Patel, MD, MPH, Rheumatologist at Massachusetts General Hospital, discusses long-term data from the AQUARIUS study of avacopan in patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). GPA is a type of vasculitis causing...
by Madaline Spencer | Nov 13, 2025
Michael Weiss, MD, Neurologist at the University of Washington, discusses data on the RAISE and RAISE-XT clinical trials of zilucoplan for the treatment of generalized myasthenia gravis (gMG). gMG is a chronic autoimmune neuromuscular disease...
